Acuta Capital Partners, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Acuta Capital Partners, LLC reported 40 stock positions worth $123.5 million. Its top holding was Vaxcyte (PCVX) at 12.5% of the portfolio, followed by Ocular Therapeutix (OCUL, 8.4%) and Tourmaline Bio (TRML, 6.9%). Compared with Q2 2024, it opened 16 new positions, sold out of 7, added to 11 and reduced 12. The biggest buy was Vaxcyte (PCVX, shares +23%) and the biggest sale Ocular Therapeutix (OCUL, shares −57%).
- Most Recent 13F
- Q2 2026
- Location
- REDWOOD CITY, CA
- CIK
- 0001582844
- Portfolio Value
- $123.5M (Q3 2024)
- SEC Filing
- 0001104659-24-118283 ↗ filed Nov 14, 2024
Holdings Value
Holdings 40 stocks · $123.5M
| PCVX Vaxcyte Inc. | 12.53% | 135,400 | $15.5M | Add +22.6% |
| OCUL Ocular Therapeutix Inc. | 8.39% | 1,190,071 | $10.4M | Reduce -57.0% |
| TRML Tourmaline Bio Inc. | 6.92% | 332,095 | $8.5M | Add +23.2% |
| INSM Insmed Inc. | 6.36% | 107,500 | $7.8M | Add +49.1% |
| ELVN Enliven Therapeutics Inc. | 6.13% | 296,368 | $7.6M | Reduce -25.5% |
| CRNX Crinetics Pharmaceuticals Inc. | 5.45% | 131,700 | $6.7M | Reduce -2.5% |
| ACLX Arcellx Inc. | 4.20% | 62,100 | $5.2M | Add +47.2% |
| MREO Mereo Biopharma Group PL-ADR | 4.20% | 1,260,700 | $5.2M | Add +86.2% |
| RVMD Revolution Medicines Inc. | 3.97% | 108,000 | $4.9M | Reduce -18.8% |
| TSHA Taysha Gene Therapies Inc. | 3.45% | 2,118,992 | $4.3M | Reduce -9.1% |
| TERN Terns Pharmaceuticals Inc. | 3.29% | 487,000 | $4.1M | Add +31.9% |
| KURA Kura Oncology Inc. | 3.12% | 197,000 | $3.8M | Add +20.9% |
| WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC | 3.09% | 1,849,402 | $3.8M | No change |
| RCKT Rocket Pharmaceuticals Inc. | 2.84% | 190,000 | $3.5M | Reduce -24.1% |
| PRAX Praxis Precision Medicines I | 2.68% | 57,500 | $3.3M | Reduce -65.0% |
| ARGX Argenx SE - ADR | 2.59% | 5,900 | $3.2M | Add +47.5% |
| ASND Ascendis Pharma A/S | 2.54% | 21,000 | $3.1M | New |
| CMPS Compass Pathways PLC | 1.97% | 386,500 | $2.4M | New |
| MERSANA THERAPEUTICS INC | 1.84% | 1,200,000 | $2.3M | Reduce -27.8% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 1.53% | 180,945 | $1.9M | Add +1.8% |
| SLRN Acelyrin Inc. | 1.45% | 364,000 | $1.8M | New |
| EWTX Edgewise Therapeutics Inc. | 1.36% | 63,000 | $1.7M | New |
| DYN Dyne Therapeutics Inc. | 1.34% | 46,200 | $1.7M | Reduce -78.3% |
| GILD Gilead Sciences Inc. | 1.32% | 19,500 | $1.6M | New |
| RARE Ultragenyx Pharmaceutical Inc. | 1.13% | 25,100 | $1.4M | New |
| TRVI Trevi Therapeutics Inc. | 0.79% | 290,500 | $970K | Add +11.7% |
| UNICYCIVE THERAPEUTICS INC | 0.65% | 1,979,199 | $807K | New |
| LQDA Liquidia Corp. | 0.60% | 73,500 | $735K | New |
| VERV Verve Therapeutics Inc. | 0.57% | 146,100 | $707K | New |
| GERN Geron Corp. | 0.57% | 154,900 | $703K | New |
| CELC Celcuity Inc. | 0.56% | 46,600 | $695K | Add +3.6% |
| ARTV Artiva Biotherapeutics Inc. | 0.55% | 44,000 | $680K | New |
| TECX Tectonic Therapeutic Inc. | 0.34% | 13,700 | $415K | New |
| CRBP Corbus Pharmaceuticals Holdi | 0.31% | 18,500 | $382K | Reduce -71.3% |
| RAPP Rapport Therapeutics Inc. | 0.29% | 17,600 | $360K | Reduce -12.0% |
| CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC | 0.25% | 120,500 | $310K | Reduce -38.2% |
| CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC | 0.22% | 54,000 | $275K | New |
| BNTC Benitec Biopharma Inc. | 0.22% | 29,800 | $274K | New |
| TVTX Travere Therapeutics Inc. | 0.22% | 19,000 | $266K | New |
| THRD Third Harmonic Bio Inc. | 0.17% | 15,508 | $210K | New |
Other holdings (1): bonds, preferreds, convertibles and warrants · $9K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 90,832 | $9K | No change |
Total filed on the 13F, all lines: $123.5M.
Portfolio Sells Q2 2024 → Q3 2024
| OCUL Ocular Therapeutix Inc. | Reduce -57.0% | 8.39% | −7.59 |
| DYN Dyne Therapeutics Inc. | Reduce -78.3% | 1.34% | −4.98 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −3.66 |
| PRAX Praxis Precision Medicines I | Reduce -65.0% | 2.68% | −3.05 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −2.86 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −2.19 |
| CRBP Corbus Pharmaceuticals Holdi | Reduce -71.3% | 0.31% | −2.15 |
| ELVN Enliven Therapeutics Inc. | Reduce -25.5% | 6.13% | −1.70 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -24.1% | 2.84% | −1.70 |
| MERSANA THERAPEUTICS INC | Reduce -27.8% | 1.84% | −0.98 |
| TSHA Taysha Gene Therapies Inc. | Reduce -9.1% | 3.45% | −0.95 |
| ORIC Oric Pharmaceuticals Inc. | Sold out | 0.00% | −0.57 |
| PLRX Pliant Therapeutics Inc. | Sold out | 0.00% | −0.42 |
| RVMD Revolution Medicines Inc. | Reduce -18.8% | 3.97% | −0.38 |
| NAMS Newamsterdam Pharma Co. NV | Sold out | 0.00% | −0.36 |
| CLRB Cellectar Biosciences Inc. | Sold out | 0.00% | −0.15 |
| RAPP Rapport Therapeutics Inc. | Reduce -12.0% | 0.29% | −0.10 |
| CYPH Cypherpunk Technologies Inc. | Reduce -38.2% | 0.25% | −0.07 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -2.5% | 5.45% | +0.35 |
Portfolio Buys Q2 2024 → Q3 2024
| PCVX Vaxcyte Inc. | Add +22.6% | 12.53% | +5.50 |
| TRML Tourmaline Bio Inc. | Add +23.2% | 6.92% | +3.99 |
| ASND Ascendis Pharma A/S | New | 2.54% | +2.54 |
| INSM Insmed Inc. | Add +49.1% | 6.36% | +2.28 |
| ACLX Arcellx Inc. | Add +47.2% | 4.20% | +2.24 |
| MREO Mereo Biopharma Group PL-ADR | Add +86.2% | 4.20% | +2.14 |
| CMPS Compass Pathways PLC | New | 1.97% | +1.97 |
| SLRN Acelyrin Inc. | New | 1.45% | +1.45 |
| EWTX Edgewise Therapeutics Inc. | New | 1.36% | +1.36 |
| GILD Gilead Sciences Inc. | New | 1.32% | +1.32 |
| TERN Terns Pharmaceuticals Inc. | Add +31.9% | 3.29% | +1.17 |
| ARGX Argenx SE - ADR | Add +47.5% | 2.59% | +1.14 |
| RARE Ultragenyx Pharmaceutical Inc. | New | 1.13% | +1.13 |
| UNICYCIVE THERAPEUTICS INC | New | 0.65% | +0.65 |
| LQDA Liquidia Corp. | New | 0.60% | +0.60 |
| VERV Verve Therapeutics Inc. | New | 0.57% | +0.57 |
| GERN Geron Corp. | New | 0.57% | +0.57 |
| ARTV Artiva Biotherapeutics Inc. | New | 0.55% | +0.55 |
| TECX Tectonic Therapeutic Inc. | New | 0.34% | +0.34 |
| KURA Kura Oncology Inc. | Add +20.9% | 3.12% | +0.29 |
| CLYM Climb Bio Inc. | New | 0.22% | +0.22 |
| BNTC Benitec Biopharma Inc. | New | 0.22% | +0.22 |
| TVTX Travere Therapeutics Inc. | New | 0.22% | +0.22 |
| THRD Third Harmonic Bio Inc. | New | 0.17% | +0.17 |
| TRVI Trevi Therapeutics Inc. | Add +11.7% | 0.79% | +0.13 |
| BBOT Bridgebio Oncology Therapeut | Add +1.8% | 1.53% | −0.00 |
| CELC Celcuity Inc. | Add +3.6% | 0.56% | −0.06 |
Options Activity Q2 2024 → Q3 2024
| SVRA Savara Inc. | put | Sold out | 250 | $101Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $143.5M | PRAX, WHWK, TNGX, STRO, AVBP |
| Q1 2026 | 26 | $140.6M | PRAX, TERN, WHWK, TNGX, DRUG |
| Q4 2025 | 29 | $147.3M | TERN, PRAX, CDTX, OCUL, WHWK |
| Q3 2025 | 27 | $96.8M | OCUL, CDTX, TRML, WHWK, INSM |
| Q2 2025 | 27 | $71.6M | OCUL, CDTX, WHWK, SLNO, TRML |
| Q1 2025 | 33 | $86.2M | OCUL, INSM, TRML, WHWK, ELVN |
| Q4 2024 | 38 | $99.4M | OCUL, INSM, TRML, CRNX, ELVN |
| Q3 2024 | 40 | $123.5M | PCVX, OCUL, TRML, INSM, ELVN |
| Q2 2024 | 31 | $118.6M | OCUL, ELVN, PCVX, DYN, PRAX |
| Q1 2024 | 32 | $153.9M | OCUL, PRAX, MERSANA THERAPEUTICS INC, TSHA, RCKT |